Schedule 13G ownership disclosure
Oramed Pharmaceuticals, Inc.
Common Stock par value $0.012 per share · CUSIP: 68403P203
Event date: 2024-12-31
- Filing-level shares
- 2,643,907
- Percent of class
- 6.55%
- BML Investment Partners, L.P.
Shares: 2,643,907 · Class: 6.55%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001373604-25-000022
- Form type
- SCHEDULE 13G/A
- Filer
- BML Investment Partners, L.P.
- CIK
- CIK 1373604
- Filed
- Feb 13, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership